Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Organon & Co.
(NY:
OGN
)
18.00
+0.02 (+0.11%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Organon & Co.
< Previous
1
2
3
Next >
Organon Reports Results for the Second Quarter Ended June 30, 2023
August 08, 2023
From
Organon & Co.
Via
Business Wire
Samsung Bioepis & Organon Announce Topline Results from Interchangeability Study of SB5 Humira Biosimilar
August 01, 2023
From
Samsung Bioepis
Via
GlobeNewswire
Organon To Report Second Quarter Results and Host Conference Call on August 8, 2023
July 17, 2023
From
Organon & Co.
Via
Business Wire
REPEAT/Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator
July 05, 2023
From
Organon
Via
Business Wire
Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator
July 01, 2023
From
Organon & Co.
Via
Business Wire
Organon Publishes FY2022 ESG Report Showcasing Progress Toward Global Sustainability Goals
June 27, 2023
From
Organon & Co.
Via
Business Wire
Organon and CAF, Development Bank of Latin America, Launch First-of-Its-Kind Collaboration to Increase Sustainable Financing in Women’s Health
June 07, 2023
From
Organon & Co.
Via
Business Wire
Organon Reports Results for the First Quarter Ended March 31, 2023
May 04, 2023
From
Organon & Co.
Via
Business Wire
Organon To Report First Quarter and Host Conference Call on May 4, 2023
April 20, 2023
From
Organon & Co.
Via
Business Wire
Organon Launches “Her Plan is Her Power,” a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist
March 07, 2023
From
Organon & Co.
Via
Business Wire
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2022
February 16, 2023
From
Organon
Via
Business Wire
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 16, 2023
February 06, 2023
From
Organon & Co.
Via
Business Wire
Organon Makes Strategic Investment in Claria Medical to Support Development of Investigational Medical Device for Minimally Invasive Hysterectomy
January 05, 2023
From
Organon & Co.
Via
Business Wire
Organon To Present at the 41st Annual J.P. Morgan Healthcare Conference
December 15, 2022
From
Organon & Co.
Via
Business Wire
Organon Appoints Kirke Weaver as General Counsel and Corporate Secretary
December 12, 2022
From
Organon & Co.
Via
Business Wire
Organon To Present at the Piper Sandler 34th Annual Healthcare Conference
November 15, 2022
From
Organon & Co.
Via
Business Wire
Organon Reports Results for the Third Quarter Ended September 30, 2022
November 03, 2022
From
Organon & Co.
Via
Business Wire
Organon To Report Third Quarter Results and Host Conference Call on November 3, 2022
October 20, 2022
From
Organon & Co.
Via
Business Wire
Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)
August 17, 2022
From
Organon & Co.
Via
Business Wire
Organon Reports Results for the Second Quarter Ended June 30, 2022
August 04, 2022
From
Organon & Co.
Via
Business Wire
Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate
July 28, 2022
From
Organon & Co.
Via
Business Wire
Organon To Report Second Quarter Results and Host Conference Call on August 4, 2022
July 21, 2022
From
Organon & Co.
Via
Business Wire
Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates
June 13, 2022
From
Organon & Co.
Via
Business Wire
On One Year Anniversary, Organon Introduces Global ESG Strategy and Commitments with Publication of Inaugural ESG Report
June 02, 2022
From
Organon & Co.
Via
Business Wire
Organon Reports Results for the First Quarter Ended March 31, 2022
May 05, 2022
From
Organon & Co.
Via
Business Wire
Organon To Report First Quarter Results and Host Conference Call on May 5, 2022
April 21, 2022
From
Organon & Co.
Via
Business Wire
Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (BV)
March 31, 2022
From
Organon & Co.
Via
Business Wire
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2021
February 17, 2022
From
Organon & Co.
Via
Business Wire
Organon Acquires Contraceptive Products, Marvelon® and Mercilon®, in the People’s Republic of China, including Hong Kong and Macau, and Agrees to Acquire these Products in Vietnam
February 16, 2022
From
Organon & Co.
Via
Business Wire
Organon antaa koko henkilökunnalleen vapaapäivän oman terveytensä edistämiseksi kansainvälisenä naisten päivänä
February 10, 2022
”Koska Covid-19-pandemialla on edelleen suhteettoman suuri vaikutus naisiin, Organon kutsuu muita organisaatioita liittymään joukkoonsa ja olemaan
Via
EIN Presswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.